Sustained Release of Antiinfectives

Abstract

Provided, among other things, is a method of treating or ameliorating pulmonary infection in a cystic fibrosis patient comprising pulmonary administration of an effective amount of a liposomal / complexed antiinfective to the patient, wherein the (i) administrated amount is 50% or less of the comparative free drug amount, or (ii) the dosing is once a day or less, or (iii) both.

Description

[0001]This application claims the priority of U.S. Provisional Application 60 / 421,923, filed Oct. 29, 2002.[0002]Certain sustained release technology suitable, for example, for administration by inhalation employs liposomes and lipid complexes to provide prolonged therapeutic effect of drug in the lung and systemically by sustained release and the ability to target and enhance the uptake of drug into sites of disease. The present invention comprises a liposomal antiinfective, and methods for treatment of pulmonary infections in cystic fibrosis (CF) patients using liposomal or lipid-complexed antiinfective. Unexpectedly, treatments with the new formulation require a significantly lower dosage than that known to have efficacy in the art.[0003]As reported in Goodman and Gilman's The Pharmaceutical Basis of Therapeutics, Eighth Edition, “Since the incidence of nephrotoxicity and ototoxicity is related to the concentration to which an aminoglycoside accumulates, it is critical to reduce ...

AI Technical Summary

Benefits of technology

[0003]As reported in Goodman and Gilman's The Pharmaceutical Basis of Therapeutics, Eighth Edition, “Since the incidence of nephrotoxicity and ototoxicity is related to the concentration to which an aminoglycoside accumulates, it is critical to reduce the maintenance dosage of these drugs in patients with impaired renal function.” Since aminoglycosides can produce vestibular or auditory dysfunction and nephrotoxicity regardless of a patient's impairments, it is important generally to reduce maintenance dosages. The present invention provides dramatic reductions in maintenance dosages.

[0004]CF patients have thick mucous and / or sputum secretions in the lungs, frequent consequential infections, and biofilms resulting from bacterial colonizations. All these fluids and materials create barriers to effectively targeting infections with antiinfectives. The present invention overcomes these barriers, and even allows reduced dosing (in amount or frequency), thereby reducing the drug load on patients.

[0005]For lung infections generally, the dosing schedule provided by the invention provides a means of reducing drug load.SUMMARY OF THE INVENTION

Problems solved by technology

All these fluids and materials create barriers to effectively targeting infections with antiinfectives.

Images